Page last updated: 2024-11-03

prazosin and Lung Diseases, Obstructive

prazosin has been researched along with Lung Diseases, Obstructive in 8 studies

Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.

Lung Diseases, Obstructive: Any disorder marked by obstruction of conducting airways of the lung. AIRWAY OBSTRUCTION may be acute, chronic, intermittent, or persistent.

Research Excerpts

ExcerptRelevanceReference
"A 51-year-old patient with COPD, obesity, and pulmonary hypertension underwent long-term prazosin therapy after a successful hemodynamic response to 1 mg of oral prazosin."7.68Long-term prazosin therapy for COPD pulmonary hypertension. ( Lewczuk, J; Piszko, P; Sobkowicz-Woźniak, B; Spikowski, J; Wrabec, K, 1992)
"The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)."7.67Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985)
"Prazosin was studied in 11 patients (10 men, 1 women) aged 63 +/- 7 years with advanced c."6.67[Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin]. ( Lewczuk, J; Palka, PS; Piszko, P; Porada, A; Sobkowicz-Woźniak, B; Spikowski, J; Szczygielski, J; Trzesicka, M; Wrabec, K, 1990)
" This doxazosin dosage reduced the diastolic blood pressure on average from 103 to 91 mmHg (P = 0."5.28Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. ( Biernacki, W; Flenley, DC, 1989)
"A single dose of capoten (25 mg) and prazosin (I mg) was given to 82 patients with stable pulmonary hypertension and chronic non-specific pulmonary diseases and to 34 patients with the above condition and arterial hypertension."5.06[Pharmacologic effects of peripheral vasodilators in patients with secondary pulmonary hypertension]. ( Abrosimov, AG; Belov, AM; Kukes, VG; Nasyrov, ShN; Tsoĭ, AN, 1989)
" In this article, doxazosin is reviewed for its efficacy in the treatment of severe essential hypertension and specific complications or conditions of mild or moderate essential hypertension, namely, left ventricular hypertrophy, hyperlipidemia, noninsulin-dependent diabetes mellitus, renal insufficiency, pheochromocytoma, chronic obstructive pulmonary disease, peripheral vascular disease, and smoking."4.78Efficacy of doxazosin in specific hypertensive patient groups. ( Taylor, SH, 1991)
"A 51-year-old patient with COPD, obesity, and pulmonary hypertension underwent long-term prazosin therapy after a successful hemodynamic response to 1 mg of oral prazosin."3.68Long-term prazosin therapy for COPD pulmonary hypertension. ( Lewczuk, J; Piszko, P; Sobkowicz-Woźniak, B; Spikowski, J; Wrabec, K, 1992)
"The effect of vasodilator therapy in chronic obstructive lung disease with pulmonary hypertension was evaluated in eight patients during oral prazosin therapy (2-10 mg day-1)."3.67Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. ( Halvorsen, FJ; Jentoft, H; Vik-Mo, H; Walde, N, 1985)
"Prazosin was studied in 11 patients (10 men, 1 women) aged 63 +/- 7 years with advanced c."2.67[Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin]. ( Lewczuk, J; Palka, PS; Piszko, P; Porada, A; Sobkowicz-Woźniak, B; Spikowski, J; Szczygielski, J; Trzesicka, M; Wrabec, K, 1990)
" This doxazosin dosage reduced the diastolic blood pressure on average from 103 to 91 mmHg (P = 0."1.28Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. ( Biernacki, W; Flenley, DC, 1989)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19904 (50.00)18.7374
1990's4 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bruynzeel, PL1
Hamelink, ML1
Kok, PT1
van der Vet, AP1
Kreukniet, J1
Lewczuk, J3
Sobkowicz-Woźniak, B2
Piszko, P2
Spikowski, J2
Wrabec, K3
Taylor, SH1
Porada, A1
Trzesicka, M1
Palka, PS1
Szczygielski, J1
Biernacki, W1
Flenley, DC1
Kukes, VG1
Tsoĭ, AN1
Abrosimov, AG1
Nasyrov, ShN1
Belov, AM1
Vik-Mo, H1
Walde, N1
Jentoft, H1
Halvorsen, FJ1

Reviews

2 reviews available for prazosin and Lung Diseases, Obstructive

ArticleYear
Efficacy of doxazosin in specific hypertensive patient groups.
    American heart journal, 1991, Volume: 121, Issue:1 Pt 2

    Topics: Adrenal Gland Neoplasms; Antihypertensive Agents; Cardiomegaly; Diabetes Mellitus, Type 2; Doxazosin

1991
[Value of vasodilator agents in the treatment of diseases with pulmonary hypertension caused by chronic obstructive lung diseases].
    Pneumonologia i alergologia polska, 1991, Volume: 59, Issue:3-4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B

1991

Trials

2 trials available for prazosin and Lung Diseases, Obstructive

ArticleYear
[Clinical and hemodynamic evaluation of 6-week treatment of pulmonary hypertension in chronic obstructive lung diseases (COLD) with low dose of prazosin].
    Kardiologia polska, 1990, Volume: 33, Issue:6

    Topics: Administration, Oral; Aged; Hemodynamics; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructiv

1990
[Pharmacologic effects of peripheral vasodilators in patients with secondary pulmonary hypertension].
    Klinicheskaia meditsina, 1989, Volume: 67, Issue:5

    Topics: Adolescent; Adult; Aged; Captopril; Clinical Trials as Topic; Hemodynamics; Humans; Hypertension, Pu

1989

Other Studies

4 other studies available for prazosin and Lung Diseases, Obstructive

ArticleYear
Alpha 2-adrenergic receptors on intact human platelets of normal individuals and chronic obstructive lung disease patients.
    European journal of respiratory diseases. Supplement, 1984, Volume: 135

    Topics: Blood Platelets; Epinephrine; Humans; Lung Diseases, Obstructive; Phentolamine; Prazosin; Receptors,

1984
Long-term prazosin therapy for COPD pulmonary hypertension.
    Chest, 1992, Volume: 102, Issue:2

    Topics: Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive; Male; Middle Aged; Obesity; Prazosin; R

1992
Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD.
    Journal of human hypertension, 1989, Volume: 3, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adult; Aged; Asthma; Blood Pressure; Doxazosin; Female; Forced Expirat

1989
Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale.
    European heart journal, 1985, Volume: 6, Issue:12

    Topics: Administration, Oral; Aged; Carbon Dioxide; Chronic Disease; Female; Hemodynamics; Humans; Hypertens

1985